戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 urces for COPD patients with moderate/severe airways obstruction.
2 the same time that the FEV1 revealed ongoing airways obstruction.
3 rrence of laryngeal lesions with the risk of airways obstruction.
4 ch was associated with reduced odds of small airways obstruction.
5 ver, only asthma is associated with variable airways obstruction.
6 imilar for patients with concomitant chronic airways obstruction.
7 uggest that excessive mucin secretion causes airways obstruction and inflammation.
8 ystals, airway fibrosis, eotaxin production, airways obstruction, and nonspecific AHR.
9 ty is mostly caused by bronchiectasis, small airways obstruction, and progressive respiratory impairm
10                             We defined small airways obstruction as either mean forced expiratory flo
11          Control and COPD subjects with mild airways obstruction (baseline FEV(1) >/= 50% predicted)
12 ry disease that is characterized by variable airways obstruction caused by acute and chronic bronchia
13 gic agonist bronchodilators to patients with airways obstruction commonly results in transient decrea
14 We aimed to estimate the prevalence of small airways obstruction, examine the associated risk factors
15 s had severe Brasfield scores (9.0 +/- 3.2), airways obstruction (FEV1 25.6 +/- 5.6% predicted, FEF(2
16 piratory volume in 1 s [FEV1]) and increased airways obstruction (FEV1 as a percentage of forced vita
17  administration of 200 mug salbutamol) small airways obstruction for each site.
18 structural component in determining variable airways obstruction in asthma.
19                                        Small airways obstruction is a common feature of obstructive l
20 rch is required to investigate whether small airways obstruction is also associated with respiratory
21 spite the wide geographical variation, small airways obstruction is common and more prevalent than ch
22                  Research is scarce on small airways obstruction, its global prevalence, and risk fac
23 Although asthma is characterized by variable airways obstruction, most studies of asthma phenotypes a
24 toplasty versus medical management for nasal airways obstruction: multicentre, open label, randomised
25       Prevalence of pre-bronchodilator small airways obstruction ranged from 5% (34 of 624 participan
26 y subjects, patients with moderate-to-severe airways obstruction receive an increased dose from ultra
27                                        Small airways obstruction shows the same risk factors as chron
28      Prevalence of post-bronchodilator small airways obstruction was universally lower.
29           To identify risk factors for small airways obstruction, we performed multivariable regressi
30                                              Airways obstruction with thick, adherent mucus is a path